Drugs / GEN-009
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03633110 | Aug 2018 → Dec 2021 | cutaneous melanoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, renal cell carcinoma +1 | Genocea Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN-009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03633110 ↗ |
| Modality | Vaccine | “investigational, personalized adjuvanted vaccine, GEN-009” NCT03633110 ↗ |